Radiopharmaceutical Platform Expansion And Pipeline Progress Will Transform Long Term Earnings Profile

Catalysts

About Telix Pharmaceuticals

Telix Pharmaceuticals develops and commercializes radiopharmaceutical imaging and therapeutic products across urologic, neuro-oncology and solid tumor indications.

What are the underlying business or industry changes driving this perspective?

• Rollout of multiple precision imaging agents such as Illuccix and Gozellix across more than 23 countries and into large markets like the U.S., Europe, China and Japan, which broadens the addressable customer base and can support revenue growth as the installed commercial footprint is used more intensively.
• Expansion from a single product, single market model into a multiproduct, multi-region platform, with Illuccix, Gozellix, Zircaix and Pixclara building on existing commercial teams and infrastructure, which can improve operating leverage and support earnings as fixed selling and administrative costs are spread over more products.
• Vertical integration in radiopharmaceutical manufacturing and last mile distribution through RLS, ARTMS, Iso Therapeutics and other TMS sites, including planned cyclotron deployment, which can reduce reliance on third parties and over time may support gross margins and supply reliability, both key inputs to sustainable earnings.
• Advancement of a broad late stage and early stage therapeutics pipeline across prostate cancer, kidney cancer, glioblastoma and other tumors, backed by increasing R&D spend and several pivotal or registration enabling trials, which, if successful, could shift the business mix toward higher value therapeutic revenue and influence long term net margins and earnings.
• Use of companion diagnostics and life cycle management programs such as the BiPASS study and AlFluor chemistry to move PSMA imaging earlier in the care pathway and cater to both gallium and F 18 user preferences, which can deepen utilization per patient and support both revenue and EBITDA resilience as markets mature.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Telix Pharmaceuticals's revenue will grow by 15.8% annually over the next 3 years.
• Analysts assume that profit margins will increase from -0.9% today to 6.6% in 3 years time.
• Analysts expect earnings to reach $81.9 million (and earnings per share of $0.26) by about June 2029, up from -$7.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $201.2 million in earnings, and the most bearish expecting $-51.0 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 82.4x on those 2029 earnings, up from -514.7x today. This future PE is greater than the current PE for the AU Biotechs industry at 21.7x.
• Analysts expect the number of shares outstanding to grow by 0.11% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.25%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Heavy reinvestment into R&D and manufacturing, including a 47% rise in R&D to $82 million and increased spend on TMS sites and cyclotrons, is already weighing on adjusted EBITDA. If management continues to prioritise long term asset building over near term EPS, reported earnings and net margins could remain under pressure for longer than you expect, even if revenues hold up.
• The SEC subpoena relating to disclosure around prostate cancer therapeutic candidates introduces regulatory and reputational uncertainty. If the process drags on or leads to tighter oversight, it could slow clinical programs, raise compliance costs or distract management, which would affect earnings and potentially delay revenue from the therapeutics pipeline.
• PSMA imaging is becoming more competitive and pricing pressure has already been flagged. If reimbursement changes, pass through status transitions and hospital buying power push prices lower faster than Telix can offset with volume and mix, Illuccix and Gozellix could face weaker average selling prices and product margins, which would hit Precision Medicine revenue and gross margin.
• The acquisitions and build out of RLS and broader TMS operations have brought in a lower gross margin business, with RLS at 7% gross margin and close to breakeven EBITDA. If Telix cannot shift a significantly larger share of its own higher margin products through that network, group gross margin and cash generation could stagnate or fall, limiting funds available to support pipeline and earnings growth.
• The broad late and early stage therapeutics portfolio across prostate, kidney, brain and other cancers is central to the long term story. If pivotal and first in human trials such as ProstACT GLOBAL, LUTEON, IPAX BrIGHT and the alpha programs are delayed, fail to show the required safety or efficacy, or face regulatory setbacks, the expected transition toward higher value therapeutic revenue would be pushed out, which would constrain future revenue growth and long term net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of A$23.36 for Telix Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$32.0, and the most bearish reporting a price target of just A$18.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $81.9 million, and it would be trading on a PE ratio of 82.4x, assuming you use a discount rate of 7.2%.
• Given the current share price of A$15.68, the analyst price target of A$23.36 is 32.9% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.